… -2 inhibitor, has shown significant cardio- and renoprotective benefits in patients with type
2 diabetes (with and without atherosclerotic cardiovascular disease), heart failure and chronic …

… death and worsening heart failure events in patients with heart failure and mildly reduced or
… Here, we explore if the effects of dapagliflozin on cardiovascular events vary according to …

… death or worsening heart failure, including heart failure hospitalization or urgent treatment
… of heart failure hospitalization or cardiovascular death, heart failure hospitalization (first and …

… To compare the effects of dapagliflozin versus placebo on the primary outcome and secondary
clinical outcomes according to NT-proBNP quartiles, time-to-event data were evaluated …

… (used in the treatment of heart failure or hypertension) would … , owing to the natriuretic effects
of dapagliflozin. At baseline, … to placebo, the favorable effects of dapagliflozin on the primary …

… heart failure … effects of dapagliflozin alone and in combination with sacubitril/valsartan (LCZ696)
or spironolactone on the function of myocardial fibroblasts of patients with heart failure …

Background Three large cardiovascular outcome trials of patients with type 2 diabetes (T2D)
found a reduction in hospitalizations for heart failure (HF) in patients treated with SGLT2i. …

… compared to patients without heart failure (and therefore the use of non-heart failure-specific
cutoffs … Short-term effects of dapagliflozin on maximal functional capacity in heart failure with …

… that improve symptoms and reduce worsening of heart failure status over time but do not have
… However, the similar effects of dapagliflozin in patients with chronic kidney disease and in …

… While not pre-specified, we also examined the effects of dapagliflozin according to …
Effects of dapagliflozin on physiologic measures and safety outcomes according to baseline …